Cover Image

Therapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis

Saved in:

Bibliographic Details
Main Authors:	Cynthia Cristina Ferreira Mota (Author), Ricardo Romiti (Author), Marcelo Arnone (Author), Andre Luís da Silva Hirayama (Author), Maria Denise Fonseca Takahashi (Author)
Format:	Book
Published:	Sociedade Brasileira de Dermatologia, 2022-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Psoriasis comorbidities: complications and benefits of immunobiological treatment
by: André Vicente Esteves de Carvalho, et al.
Published: (2016)

Psoríase na infância e na adolescência Psoriasis in childhood and adolescence
by: Ricardo Romiti, et al.
Published: (2009)

Infections in the era of immunobiologicals
by: Ricardo Romiti, et al.
Published: (2024)

Generalized pustular psoriasis (von Zumbusch)
by: Ricardo Romiti, et al.
Published: (2022)

Survival of immunobiological drugs in psoriasis: preliminary data from a Tertiary Hospital experience in Southern Brazil
by: Elis Costa de Lima, et al.
Published: (2021)

New therapeutic targets for the management of moderate-severe psoriasis
by: José C. Ruiz-Carrascosa, et al.
Published: (2022)

Evaluation of renal function in patients with psoriasis using immunobiologicals
by: Sarah Suyanne Carvalho Melgaco, et al.
Published: (2013)

Case series: psoriasis in solid organ transplant patients and immunobiological agents
by: Luana Pizarro Meneghello, et al.
Published: (2023)

Two cases of renal cell cancer during immunobiologic therapy for psoriasis
by: Fabiana Palmieri Zarur, et al.
Published: (2014)

Immunobiology of Leishmaniasis
Published: (2020)

Immunobiologicals in dermatology
by: Dimitri Luz Felipe da Silva, et al.
Published: (2022)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
by: Audrey Melin, et al.
Published: (2021)

Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience
by: Rosés Gibert P, et al.
Published: (2022)

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
by: Kim Papp, et al.
Published: (2022)

Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology
by: Marcelo Arnone, et al.

Immunobiology and immunotherapy of gestational trophoblastic disease
by: Neha Sharma, et al.
Published: (2022)

IMMUNOBIOLOGICAL CONTROL SYSTEM AND IMMUNOPATHOLOGICAL SYNDROMES
by: P.F. Litvitsky
Published: (2007)

IMMUNOBIOLOGICAL CONTROL SYSTEM AND IMMUNOPATHOLOGICAL SYNDROMES
by: P.F. Litvitsky
Published: (2007)

The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
Published: (2020)

Evaluation of Reference Centers for Special Immunobiologicals implementation
by: Laura Andrade Lagôa Nóbrega, et al.
Published: (2016)

Validity of an instrument to evaluate the immunobiological cold chain
by: Maíla Martins Oliveira, et al.
Published: (2020)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016)

Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
by: Bucur S, et al.
Published: (2024)

Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
by: Ting-Shun Wang, et al.
Published: (2013)

Cell-Cell and Cell-Matrix Adhesion in Immunobiology and Cancer
Published: (2020)

Understanding Immunobiology Through the Specificity of NF-κB
Published: (2020)

REGISTRATION OF DATA ON THE USE OF IMMUNOBIOLOGICALS AND SUPPLIES IN VACCINE ROOMS
by: Taís Trombetta Dalla Nora, et al.
Published: (2018)

Overview of (1→3)-β-D-glucan immunobiology
by: David L. Williams
Published: (1997)

Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption
by: Anna Campanati, et al.
Published: (2019)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013)

Anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis
by: Julia S. Kovaleva, et al.
Published: (2024)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023)

The psychological and immunobiological implications of COVID-19: The possible correlation with previous pandemics and the suggestive therapeutic hypothesis of convalescent plasma
by: Giulio Perrotta
Published: (2021)

Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France - the POP study
by: A. P. Villani, et al.
Published: (2023)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
by: Chiricozzi A, et al.
Published: (2019)

Disease severity in moderate‐to‐severe plaque psoriasis: Results from the Belgian REDISCOVER study
by: Tom Hillary, et al.
Published: (2024)

Optic neuritis due to immunobiologics: first Brazilian case report
by: Luiz Gustavo Martins da Silva, et al.
Published: (2013)

Retail of veterinary immunobiological preparations on the Ukrainian market of veterinary vaccines
by: I. V. Bushuieva, et al.
Published: (2020)